• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

性别对非小细胞肺癌切除术后生存的影响:日本肺癌登记研究中 12509 例回顾性分析。

Survival differences by gender for resected non-small cell lung cancer: a retrospective analysis of 12,509 cases in a Japanese Lung Cancer Registry study.

机构信息

Division of Thoracic Surgery, National Cancer Center Hospital, Chuo-ku, Tokyo, Japan.

出版信息

J Thorac Oncol. 2010 Oct;5(10):1594-601. doi: 10.1097/JTO.0b013e3181f1923b.

DOI:10.1097/JTO.0b013e3181f1923b
PMID:20736855
Abstract

INTRODUCTION

Women with non-small cell lung cancer (NSCLC) are more likely to have better survival than men. This study intended to assess gender differences in the survival of these patients in a large registry population.

METHODS

In 2005, the Japanese Joint Committee for Lung Cancer Registration performed a nationwide retrospective registry study regarding the prognosis and clinicopathologic profiles of patients who underwent resection for primary lung neoplasms in 1999. The registry data of 12,509 patients with NSCLC were analyzed in terms of gender differences in prognosis and clinicopathologic features.

RESULTS

There were 8353 (66.8%) men and 4156 (33.2%) women with a mean age at operation of 66.4 and 65.0 years, respectively (p < 0.001). Women had a higher incidence of adenocarcinoma (p < 0.001) and stage IA disease (p < 0.001) than men. The overall survival was significantly better in women than men. The 5-year survival rates (5-YSRs) for women and men were 75.6 and 57.9%, respectively (p = 0.0000). According to histology, the overall survival of women was significantly better than that of men for both adenocarcinoma (5-YSR, 77.7 versus 61.9%, p = 0.0000) and nonadenocarcinoma (5-YSR, 59.3 versus 53.1%, p = 0.035). In adenocarcinoma, women had a significantly better prognosis than men for pathologic stage I/II disease. However, in nonadenocarcinoma, there was no significant prognostic difference between the two genders in pathologic stage I/II disease.

CONCLUSIONS

Women with NSCLC, especially with an adenocarcinoma histology, had better survival than men. Women were more likely to have adenocarcinoma and stage IA disease, which might account for the better prognosis in women.

摘要

介绍

与男性相比,患有非小细胞肺癌(NSCLC)的女性患者的生存情况更有可能更好。本研究旨在评估在大型登记人群中,这些患者的生存情况存在哪些性别差异。

方法

2005 年,日本肺癌登记联合委员会针对 1999 年接受原发性肺肿瘤切除术的患者的预后和临床病理特征进行了一项全国性回顾性登记研究。对 12509 例 NSCLC 患者的登记数据进行了分析,以评估预后和临床病理特征方面的性别差异。

结果

男性患者 8353 例(66.8%),女性患者 4156 例(33.2%),手术时的平均年龄分别为 66.4 岁和 65.0 岁(p<0.001)。女性患者的腺癌(p<0.001)和 IA 期疾病(p<0.001)的发生率更高。女性患者的总生存率明显高于男性患者。女性和男性患者的 5 年生存率(5-YSR)分别为 75.6%和 57.9%(p=0.0000)。根据组织学类型,女性腺癌(5-YSR 为 77.7%对 61.9%,p=0.0000)和非腺癌(5-YSR 为 59.3%对 53.1%,p=0.035)的总体生存率明显优于男性患者。在腺癌中,女性患者的病理分期 I/II 期疾病的预后明显优于男性患者。然而,在非腺癌中,两个性别在病理分期 I/II 期疾病方面没有显著的预后差异。

结论

患有 NSCLC 的女性患者,特别是患有腺癌的女性患者,其生存情况明显好于男性患者。女性患者更有可能患有腺癌和 IA 期疾病,这可能是女性患者预后较好的原因。

相似文献

1
Survival differences by gender for resected non-small cell lung cancer: a retrospective analysis of 12,509 cases in a Japanese Lung Cancer Registry study.性别对非小细胞肺癌切除术后生存的影响:日本肺癌登记研究中 12509 例回顾性分析。
J Thorac Oncol. 2010 Oct;5(10):1594-601. doi: 10.1097/JTO.0b013e3181f1923b.
2
Pulmonary resection in patients aged 80 years or over with clinical stage I non-small cell lung cancer: prognostic factors for overall survival and risk factors for postoperative complications.80 岁及以上临床Ⅰ期非小细胞肺癌患者的肺切除术:总生存的预后因素和术后并发症的危险因素。
J Thorac Oncol. 2009 Oct;4(10):1247-53. doi: 10.1097/JTO.0b013e3181ae285d.
3
Surgical outcome of stage IIIA- cN2/pN2 non-small-cell lung cancer patients in Japanese lung cancer registry study in 2004.2004 年日本肺癌注册研究中 IIIA-cN2/pN2 期非小细胞肺癌患者的手术治疗结果。
J Thorac Oncol. 2012 May;7(5):850-5. doi: 10.1097/JTO.0b013e31824c945b.
4
Comparison between segmentectomy and larger resection of stage IA non-small cell lung carcinoma.IA期非小细胞肺癌肺段切除术与更大范围切除术的比较。
J Cardiovasc Surg (Torino). 2004 Feb;45(1):67-70.
5
Prognostic impact of number of resected and involved lymph nodes at complete resection on survival in non-small cell lung cancer.完全切除时切除和累及的淋巴结数量对非小细胞肺癌生存的预后影响。
J Thorac Oncol. 2011 Nov;6(11):1865-71. doi: 10.1097/JTO.0b013e31822a35c3.
6
Japanese Lung Cancer Registry Study: first prospective enrollment of a large number of surgical and nonsurgical cases in 2002.日本肺癌注册研究:2002 年首次前瞻性纳入大量手术和非手术病例。
J Thorac Oncol. 2010 Sep;5(9):1369-75. doi: 10.1097/JTO.0b013e3181e452b9.
7
Survival and treatment of non-small cell lung cancer stage I-II treated surgically or with stereotactic body radiotherapy: patient and tumor-specific factors affect the prognosis.接受手术或立体定向体部放疗的Ⅰ-Ⅱ期非小细胞肺癌的生存及治疗:患者和肿瘤特异性因素影响预后。
Ann Surg Oncol. 2015 Jan;22(1):316-23. doi: 10.1245/s10434-014-3860-x. Epub 2014 Jun 25.
8
Node-negative non-small cell lung cancer: pathological staging and survival in 1765 consecutive cases.淋巴结阴性非小细胞肺癌:1765 例连续病例的病理分期和生存情况。
J Thorac Oncol. 2011 Oct;6(10):1691-6. doi: 10.1097/JTO.0b013e31822647fd.
9
Complications and outcomes after pulmonary resection for cancer in patients 80 to 89 years of age.80至89岁癌症患者肺切除术后的并发症及转归
Eur J Cardiothorac Surg. 2005 Sep;28(3):380-3. doi: 10.1016/j.ejcts.2005.06.010.
10
The prognostic value of ratio-based lymph node staging in resected non-small-cell lung cancer.基于比例的淋巴结分期在可切除非小细胞肺癌中的预后价值。
J Thorac Oncol. 2013 Apr;8(4):429-35. doi: 10.1097/JTO.0b013e3182829c16.

引用本文的文献

1
Single-Cell Transcriptomic Analysis Unveils Key Regulators and Signaling Pathways in Lung Adenocarcinoma Progression.单细胞转录组分析揭示肺腺癌进展中的关键调节因子和信号通路。
Biomedicines. 2025 Jun 30;13(7):1606. doi: 10.3390/biomedicines13071606.
2
Comparative survival analysis of stage T1-T2N0M0 lung squamous cell carcinoma and adenocarcinoma using SEER data, and nomogram analysis for early-stage lung squamous cell carcinoma.利用监测、流行病学和最终结果(SEER)数据对T1-T2N0M0期肺鳞状细胞癌和腺癌进行生存比较分析,并对早期肺鳞状细胞癌进行列线图分析。
Transl Cancer Res. 2025 Mar 30;14(3):1691-1709. doi: 10.21037/tcr-24-1602. Epub 2025 Mar 27.
3
Sex-based differences in lung cancer susceptibility and molecular genetics in the 2020s.
21世纪20年代肺癌易感性和分子遗传学中的性别差异。
Heliyon. 2025 Jan 17;11(2):e42089. doi: 10.1016/j.heliyon.2025.e42089. eCollection 2025 Jan 30.
4
ERS Congress 2024: highlights from the Thoracic Surgery and Lung Transplantation Assembly.2024年欧洲呼吸学会大会:胸外科与肺移植大会亮点
ERJ Open Res. 2025 Jan 27;11(1). doi: 10.1183/23120541.01046-2024. eCollection 2025 Jan.
5
Insights into sex differences in perioperative outcomes of non-small cell lung cancer patients.非小细胞肺癌患者围手术期结局的性别差异洞察
Transl Lung Cancer Res. 2024 Oct 31;13(10):2549-2560. doi: 10.21037/tlcr-24-336. Epub 2024 Oct 23.
6
Impact of CA9 expression in the diagnosis of lymph-node metastases in non-small cell lung cancer based on [18F]FDG PET/CT.基于[18F]FDG PET/CT 的 CA9 表达对非小细胞肺癌淋巴结转移诊断的影响。
PLoS One. 2024 Oct 29;19(10):e0312846. doi: 10.1371/journal.pone.0312846. eCollection 2024.
7
[Gender medicine in lung diseases].[肺部疾病中的性别医学]
Chirurgie (Heidelb). 2024 Sep;95(9):730-735. doi: 10.1007/s00104-024-02141-7. Epub 2024 Aug 1.
8
Age at lung cancer diagnosis in females versus males who never smoke by race and ethnicity.女性与从不吸烟的男性肺癌诊断年龄比较,按种族和民族划分。
Br J Cancer. 2024 May;130(8):1286-1294. doi: 10.1038/s41416-024-02592-z. Epub 2024 Feb 22.
9
Nationwide prospective registry database of patients with newly diagnosed untreated pleural mesothelioma in Japan.日本新诊断未经治疗的胸膜间皮瘤患者的全国前瞻性登记数据库。
Cancer Sci. 2024 Feb;115(2):507-528. doi: 10.1111/cas.16021. Epub 2023 Dec 4.
10
Observed and relative survival trends of lung cancer: A systematic review of population-based cancer registration data.肺癌观察生存率和相对生存率趋势:基于人群的癌症登记数据的系统评价。
Thorac Cancer. 2024 Jan;15(2):142-151. doi: 10.1111/1759-7714.15170. Epub 2023 Nov 20.